Author

Martine C. J. Abrahamse-Testroote

Observed names: M C J Abrahamse-Testroote, Martine Abrahamse-Testroote, Martine C J Abrahamse-Testroote

Institution: Hovon

Observed institutions: Erasmus MC, Hovon

ORCID: 0000-0003-1574-489X

Observed ORCID: 0000-0003-1574-489X

OpenAlex ID: A5006469684

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL

2014 · Christian H. Geisler, Mars B. van t’ Veer, et al. · Blood · 51

Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study

2023 · Jacoline E C Bromberg, Samar Issa, et al. · Neuro-Oncology · 26

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

2017 · Fie J. Vojdeman, Sarah E. M. Herman, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 16

Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study

2016 · M van Gelder, M H van Oers, et al. · Bone Marrow Transplantation · 15

The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia

2016 · Fie Juhl Vojdeman, Mars B. van't Veer, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 13

Fixed-duration ibrutinib–venetoclax with MRD-guided ibrutinib–obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial

2025 · Arnon P Kater, Sabina Kersting, et al. · The Lancet Haematology · 6

Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

2024 · Mark-David Levin, Sabina Kersting, et al. · Blood · 6

Performance Status and Comorbidity Affect Survival in Elderly Patients With Cll After Low Dose Alemtuzumab Combined With Chemotherapy : Results From the Hovon68 Trial

2016 · Fie Juhl Vojdeman, M. van't Veer, et al. · Data Archiving and Networked Services (DANS)

Works count: 8

Citation count: 133

H-index: 6

I10-index: 5